Norway’s Xellia Pharma Acquired By Novo A/S In $700 Million Buyout
This article was originally published in The Pink Sheet Daily
Executive Summary
3i sells Nordic antibacterial manufacturer Xellia Pharmaceuticals, which has plans to develop novel antibiotics, new formulations and new bulk generics.